A phase 1/2 trial of AT-1965 Liposome Injection in advanced solid tumours, run by Alyssum Therapeutics, now recruiting.
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors is a phase 1/2 interventional study registered as NCT06234098 by Alyssum Therapeutics, with 100 participants planned, started 2024-02-13 and due to reach its primary completion in 2026-12. Interventions recorded: AT-1965 Liposome Injection.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.